Michele Reni, MD

GI Oncology Now

<p>Michele Reni, MD, Oncology Scientific Institute San Raffaele, breaks down the CASSANDRA study, a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III pancreatic ductal adenocarcinoma.<p>Dr. Reni comments on the 3-year event-free survival doubling from 14% with mFOLFIRINOX to 30% with PAXG, how practice-changing this may be, and more.</p></p>


Devalingam Mahalingam, PhD

Elraglusib With Gem/Nab-Paclitaxel for Previously Untreated Metastatic Pancreatic Cancer

Pancreatic Cancer

Lauren Dembeck, PhD

Clinical Profile of Long-Term Survivors May Be Informative for Treatment in Metastatic Pancreatic Cancer

PANOVA-3 Shows Tumor-Treating Fields Extend Survival in Locally Advanced Pancreatic Cancer

Latest News

CASSANDRA: Neoadjuvant PAXG Versus mFOLFIRINOX for Resectable, Borderline Resectable PDAC

Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG  for stage I-III PDAC.

CASSANDRA: Neoadjuvant PAXG Versus mFOLFIRINOX

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable